Altered levels of cytokines in patients with irritable bowel syndrome are not correlated with fatigue by Vara, Ellen Johanne et al.
© 2018 Vara et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. 
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work 
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For 
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
International Journal of General Medicine 2018:11 285–291
International Journal of General Medicine Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
285
O R I G I N A L  R E S E A R C H
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/IJGM.S166600
Altered levels of cytokines in patients with 






1Centre of Nutrition, Department 
of Clinical Medicine, University 
of Bergen, Bergen, Norway; 
2Broegelmann Research Laboratory, 
Department of Clinical Science, 
University of Bergen, Bergen, Norway; 
3Section of Gastroenterology, 
Haukeland University Hospital, 
Bergen, Norway; 4National Centre of 
Functional Gastrointestinal Disorders, 
Haukeland University Hospital, 
Bergen, Norway
Introduction: A considerable number of patients with gastrointestinal complaints attributable to 
irritable bowel syndrome (IBS) have shown evidence of immune activation. Fatigue is also frequently 
reported by IBS patients and the condition is considered as a common comorbidity of IBS. Therefore, 
it is interesting to see whether these two conditions share the same pathophysiological mechanism.
Aims: To investigate the potential role of cytokine profiles in patients with IBS and the relation-
ship between cytokine profiles and fatigue.
Materials and methods: Thirty-eight patients with IBS (32 females, 6 males, age range 18–70 
years) and 22 healthy individuals (control group) (17 females, 5 males, age range 24–42 years) 
were included. IBS was diagnosed according to Rome III criteria, and severity of IBS symptoms 
and fatigue were evaluated using the Irritable Bowel Syndrome-Severity Scoring System (IBS-
SSS) and Fatigue Impact Scale (FIS), respectively. FIS scores of 25 or higher were defined as 
fatigue. Blood samples were also taken, and the Luminex® platform (Cytokine Human Ultrasensi-
tive Magnetic 10-Plex Panel) was used for quantifying human cytokines’ profile (granulocyte-
macrophage colony-stimulating factor, interferon-γ, interleukin [IL]-1β, IL-2, IL-4, IL-5, IL-6, 
IL-8, IL-10, and tumor necrosis factor [TNF]-α) in serum.
Results: The serum levels of IL-5, IL-6, IL-10, and TNF-α were significantly higher in patients 
with IBS compared to healthy controls (p=0.003, p=0.011, p=0.007, and p=0.02, respectively). 
Conversely, serum levels of cytokine IL-1β were significantly higher in the control group (p=0.03). 
The findings were consistent when comparing nonatopic patients with controls. Fatigue was 
demonstrated in 84.2% of the IBS patients. Scores of IBS-SSS were not significantly correlated 
with FIS scores (r=0.2, p=0.19), and they were not significantly different in patients with FIS 
scores >25 compared to patients with FIS scores <25 (p=0.11). None of the cytokine levels 
were significantly different in IBS patients with FIS scores >25 compared to IBS patients with 
FIS scores <25. Moreover, the cytokine levels in participants did not vary significantly between 
patients with diarrhea, constipation, or mixed bowel habits in multiple comparisons of patients.
Conclusions: The cytokines IL-5, IL-6, IL-10, and TNF-α may contribute to the development 
of IBS. However, serum levels of cytokines were not significantly different in IBS patients with 
fatigue compared with IBS patients without fatigue. Thus, the significance of cytokine levels 
may be less important than anticipated in search of common underlying mechanisms, and other 
factors should be explored in future studies.
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Introduction
Irritable bowel syndrome (IBS) is a common functional gastrointestinal (GI) disorder with 
a prevalence rate of ~10%–15% in the Western world.1,2 The condition is  characterized 
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by pain or discomfort in the abdomen, flatulence, and altered 
bowel habits as diarrhea, constipation, or changing between 
constipation and diarrhea. In addition to abdominal symptoms, 
IBS is commonly associated with extraintestinal symptoms and 
comorbidities, such as fatigue and fibromyalgia.1,3,4 Fatigue 
symptoms are described by patients as a long-lasting tired-
ness or weakness and can be experienced both physically and 
mentally. Fatigue is often observed to have a vast impact on 
patients’ daily life and is associated with decreased quality of 
life.5 In addition, fatigue is experienced by many patients with 
IBS, and patients with functional GI disorders often report 
more severe fatigue than patients with organic disease and 
controls.1,5,6 The underlying mechanisms of fatigue are proven 
to be both biological and psychological, and the proposed fac-
tors are immunological, such as proinflammatory cytokines, 
and genetically susceptible.7 Studies in patients with chronic 
fatigue have shown improvement of symptoms after B-cell 
depletion therapy, supporting the hypothesis of a potential 
immune dysfunction in patients with fatigue.8
A considerable number of patients with GI complaints 
compatible with IBS symptoms have shown evidence of 
immune activation.2,9 Measurements of the immune system 
have also been studied in search for fatigue biomarkers, and 
evidence from a previous study has shown that inflamma-
tion and immune activation play an important role in the 
development of IBS.8 Moreover, studies from Haukeland 
University Hospital have reported an increased develop-
ment of IBS symptoms and chronic fatigue in patients after 
Giardia lamblia infection.10–13 The study concluded that 
patients infected with the bacteria developed postinfectious 
IBS, suggesting that activation of the immune system plays 
an important role in the development of GI symptoms and 
fatigue in IBS patients. Consequently, the question is how 
the immune system is activated in IBS patients and if this 
affects symptoms of fatigue. A reduced expression of genes 
linked to cytokine secretion for a number of key cytokines 
has been observed in the colonic mucosa of patients reporting 
IBS symptoms, indicating that immunological differences in 
the human intestinal mucosa could induce GI complaints.14
As a result of observing familiar immunological factors in 
patients with fatigue and IBS, a common underlying patho-
physiological mechanism explaining these comorbidities has 
been proposed. Thus, the aims of this study were to investi-
gate the potential role of cytokines, granulocyte-macrophage 
colony-stimulating factor (GM-CSF), interferon (IFN)-γ, 
interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, and 
TNF-α, in patients with IBS and to examine if cytokine levels 




Thirty-eight patients referred to Section of Gastroenterology, 
Department of Medicine at Haukeland University Hospital 
for GI complaints were asked to participate. Patients filled in 
validated questionnaires to assess GI symptoms and fatigue 
during their consultations. Patients with recent intake of 
nonsteroidal anti-inflammatory drugs, organic diseases, and 
pregnant and lactating women were excluded. No age criteria 
were addressed.
In addition, a control group consisted of 22 volunteers 
who claimed to be healthy was included. They filled in 
questionnaires regarding abdominal complaints (Irritable 
Bowel Syndrome-Severity Scoring System [IBS-SSS]) and 
allergic diseases including a history of atopy, but they were 
not examined otherwise.
All patients and controls received written and oral 
information, and participating patients provided a signed 
consent. The study has been approved by the Regional 
Committees for Medical and Health Research Ethics (REC 
West, Norway).
Questionnaires
The following questionnaires were filled out by participat-
ing patients: 1) the short form of the Rome III criteria for 
diagnosing of IBS,15 2) the IBS-SSS to assess severity of IBS 
symptoms,16 and 3) the Fatigue Impact Scale (FIS) to grade 
the severity of chronic fatigue.
The IBS-SSS contains five questions regarding frequency 
and intensity of abdominal pain, severity of abdominal disten-
sion, dissatisfaction with bowel habits, and interference of 
IBS with daily life. The questions were rated on 100-point 
visual analog scales, with a maximum score of 500.16 All 
five components contributed equally. It has been established 
in previous studies that IBS-SSS scores <75 are equivalent 
to no IBS, scores <175 indicate mild IBS symptoms, scores 
ranging from 175 to 300 indicate moderate symptoms, 
and scores >300 represent severe IBS.16 Patients were also 
subclassified into diarrhea-predominant (IBS-D) group, 
constipation-predominant (IBS-C) group, and those with 
mixed/alternating bowel habits (IBS-M).
The FIS questionnaire is considered to be a reliable and 
valid tool to measure the influence of fatigue in patients. 
It is a two-part questionnaire used to assess the impact of 
fatigue on the patient’s daily life.17 The scale is constructed 
to include three subscales assessing perceived fatigue impact 
on cognitive functioning (10 items), physical functioning 
(10 items), and psychosocial functioning (20 items). The 
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Cytokines and fatigue in IBS
to 4 = extreme problems), giving a maximum FIS score of 
160. A FIS score ≥25 was defined as fatigue in accordance 
with a previous study.6
Blood samples
In all participants, blood samples were taken for measuring 
levels of cytokines and allergen-specific immunoglobulin E 
(IgE) antibodies in serum. Gel tubes were used to take blood 
samples for cytokine analysis in serum. The samples were 
centrifuged 30 minutes within 2 hours after phlebotomy, and 
serum for later analyses was frozen at −80°C degrees. The 
Cytokine Human Ultrasensitive Magnetic 10-Plex Panel 
for the Luminex® platform (Thermo Fisher Scientific, Oslo, 
Norway) was used for quantification of cytokines GM-CSF, 
IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, and TNF-α 
in serum. They were measured according to the manufac-
turer’s instructions and expressed as pg/mL.
Specific IgE antibodies to inhalant allergens were also 
measured using Phadiatop© (birch, timothy, Cladosporium 
herbarum, cat, dog, horse, mugwort, and Dermatophagoides 
pteronyssinus) in the patient group, and atopic sensitization 
was defined as having increased levels of IgE antibodies 
(≥0.35 kUA/L) to at least one allergen.
Statistical analyses
All statistical analyses were performed using the GraphPad 
Prism 6 statistical software package (GraphPad Software, 
Inc., San Diego, CA, USA) and Statistical Product and 
Service Solutions, version 25 (IBM SPSS Statistics 21 Inc., 
Chicago, IL, USA). Nonparametric statistical tests were 
conducted when analyzing the data material. Descriptive 
statistics were calculated and pairwise comparisons between 
groups were performed with the Mann-Whitney U-test. The 
continuous variables from the Mann–Whitney U-test are 
reported as medians (25th–75th percentiles). Correlations 
between different parameters within the same group were 
evaluated by Spearman’s correlation coefficient. Linear 
regression models were used to evaluate the association 
between scores of IBS-SSS and FIS, adjusting for gender and 
age in multivariate regression models. Kruskal–Wallis tests 
were performed for multiple comparisons between variables. 




Clinical and demographic data for the patient group are 
presented in Table 1.
A control group of 22 healthy individuals were included. 
The mean age among healthy individuals was 32 years (age 
range: 24–42 years) and 77% of them were women (17 
female and 5 men).
Profile of cytokines
The serum levels of IL-5, IL-6, IL-10, and TNF-α were 
significantly higher in patients with IBS compared with 
a healthy control group (p=0.003, p=0.011, p=0.007, and 
p=0.02, respectively; Figure 1). Conversely, serum levels of 
cytokine IL-1β were significantly higher in the control group 
(p=0.03). Figure 2 illustrates the spread of IL-1β in the patient 
group and among controls. Otherwise, other cytokines, such 
as GM-CSF, IFN-γ, IL-2, IL-4, and IL-8, did not significantly 
differ between the groups.
No significant correlations were observed between IBS-
SSS scores and levels of cytokines in serum in IBS patients. 
However, correlation analysis revealed significant correla-
tions between age and serum levels of IL-4 and IL-5 in the 
patient group (p=0.04 and 0.004, respectively).
Serum levels of cytokine did not differ significantly when 
comparing female patients with male patients, nor when 
comparing patients with diarrhea to patients with constipation 
and mixed bowel habits in multiple comparisons.
Fatigue and IBS-symptom severity scores
Thirty-two patients (84.2%) had fatigue as having FIS score 
≥25. No significant correlation was observed between scores 
of IBS-SSS and FIS in the patient group (r=0.2, p=0.19; 
Table 1 Demographic and clinical data in the patient cohort
Characteristics
Patients, total number 38
Females 84.2% (n=32)
Males 15.8% (n=6)
Age (years), mean (range) 34.7 (18–70)
Duration of symptoms (years), mean (range) 8.2 (1–30)
Atopic sensitized 50% (n=19)
IBS-SSS, mean (range) 288.8 (70–440)
≥300 (severe) 39.5% (n=15)
175–300 (moderate) 52.6% (n=20)
75–<175 (mild) 5.3% (n=2)
<75 (no IBS) 2.6% (n=1)
IBS subgroups
Predominant diarrhea 34.2% (n=13)
Predominant constipation 21.1% (n=8)
Mixed constipation/diarrhea 44.7% (n=17)
Fatigue
Mean FIS (range) 69.8 (9–157)
FIS ≥25 84.2% (n=32)
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 Figure 3). FIS scores were not significantly different in 
patients with FIS scores ≥25 compared to patients with FIS 
scores <25. Moreover, FIS scores were not significantly 
associated with IBS-SSS scores in the patient group in a 
multivariate regression analysis adjusting for sex and age 
(b=0.373, p=0.28).
Fatigue and cytokines
All cytokines levels have been compared according to degree 
of fatigue, and none of the serum levels of cytokines were sig-
nificantly different in patients with fatigue (FIS scores ≥25) 
compared with patients without fatigue (FIS scores <25).
Analysis of cytokine levels in stratified 
patient group
Stratified patient sampling according to atopic sensitization 
was performed in order to investigate significant associations 
in nonatopic patients. Consistent with previous findings, 
serum levels of cytokines IL-5, IL-6, IL-10, and TNF-α were 
higher in patients, whereas IL-6 and TNF-α were found to 
be significantly higher in patients compared with controls 
(p=0.008 and p=0.015, respectively). In addition, serum 
 levels of cytokine IL-1β were significantly higher in the con-
trol group compared with nonatopic IBS patients (p=0.02).
Discussion
This study attempted to find a common pathophysiological 
mechanism by investigating the potential role of cytokine 
profiles in the development of IBS and the relationship with 
Figure 1 The serum levels of cytokines IL-5 (A), IL-6 (B), IL-10 (C), and TNF-α (D) in patients with irritable bowel syndrome and controls.
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Cytokines and fatigue in IBS
fatigue, which is one of the comorbidities of IBS. Among 
the 10 different proinflammatory cytokines, the serum 
levels of IL-5, IL-6, IL-10, and TNF-α were significantly 
higher in patients with IBS, but the serum levels of IL-1β 
were significantly higher in healthy individuals when they 
were compared. The findings were consistent when compar-
ing nonatopic patients with controls. None of the cytokine 
levels were significantly different in IBS patients with and 
without fatigue. Moreover, the cytokine levels did not vary 
significantly between genders and between patients with 
diarrhea, constipation, and mixed bowel habits in multiple 
comparisons of patients.
Fatigue is one of the most common “extraintestinal” com-
plaints of patients with IBS, but it is still poorly understood. 
The biggest causes of health care costs of patients with IBS 
are non-GI symptoms (eg, fatigue, depression, and anxiety). 
Fatigue in IBS was described with a wide range of definitions, 
such as tiredness, extreme weariness, and a state of exhaustion. 
Fatigue is likely to interfere with work productivity, health-
related quality of life, cost effectiveness, and daily activity 
in this patient group.8 It is challenging to provide effective 
fatigue management for patients with IBS because there is 
a lack of research and information about fatigue compared 
with other IBS symptoms, such as abdominal pain, diarrhea, 
constipation, and psychological distress.8 Furthermore, IBS 
and the most common comorbidities share a number of 
demographic and clinical features, such as a predominance 
of female gender, the presence of enhanced fatigue, and sleep 
disturbances, and the occurrence of psychological comorbidi-
ties, such as anxiety and depression.6 This could lead one to 
speculate that all of these disorders share a common underly-
ing pathophysiological mechanism. However, the underlying 
mechanisms still remain unclear, although previous studies 
have revealed immune activation in IBS patients, suggesting 
that immunological alterations or imbalances could constitute 
causes of inducing symptoms of IBS as well as fatigue.2,14,18,19 
Recently, we examined the association between functional GI 
complaints and levels of total IgE in serum of IBS patients 
with extraintestinal symptoms; however, no significant 
associations were found.20 Thus, in compliance with previ-
ous studies implying associations between proinflammatory 
cytokines and IBS,19 we wanted to explore the association 
between the immunological cytokines GM-CSF, IFN-γ, IL-1β, 
IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, and TNF-α in serum and 
the comorbidities of IBS and fatigue. We found that patients 
with IBS had significantly higher serum levels of IL-5, IL-6, 
IL-10, and TNF-α, and significantly lower serum levels of 
IL-1β compared with controls. This is not in line with pre-
vious studies as they found low serum levels of IL-10 and 
high serum levels of IL-1β in IBS patients.21,22 Nevertheless, 
all these suggest that there is a kind of abnormal immune 
regulation, supporting the presence of immune activation in 
IBS patients. However, we do not yet know how the immune 
system is activated and it is, therefore, difficult to draw any 
conclusion from the findings. In addition, in our study, no 
significant associations were found between cytokine levels 
and IBS-SSS, or between cytokine levels and fatigue. This 
could indicate that there is no significant association between 
plasma cytokine profiles and symptom generation in IBS 
patients with fatigue. This is in accordance with previous 
studies19,23 and may suggest that cytokine levels have a less 
important role in determining the nature of the comorbidi-
ties of fatigue and IBS than predicted. Even though Scully 
et al found increased serum levels of IL-1β and TNF-α in 
IBS patients with extraintestinal comorbidities (fibromyal-
gia, premenstrual dysmorphic disorder, and chronic fatigue 
syndrome),19 there was no evidence for associations between 
cytokine profiles and the nature of the comorbidity or the 
number of extraintestinal comorbidities present.
Newer studies are linking GI complaints and immune 
dysfunctions with alterations of the gut microbiota.19 It is 
well known that the bacterial flora colonizing the GI tract 
play a major role in processing nutrients, regulating, and 
maintaining the immune system, as well as having a central 
nervous system function, for example, the “gut–brain” axis. 
Moreover, overgrowth or imbalance of specific bacterial 
strains have been associated with a variety of disorders, such 
as IBS, Crohn’s disease, allergies, and other autoimmune 
Figure 3 The correlation between IBS-SSS and FIS scores in patients with irritable 
bowel syndrome (nonsignificant; r=0.2, p=0.19).
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diseases.24,25 Thus, it is conceivable that alterations in the gut 
microbiota have clinical significance in the pathophysiology 
and the symptom generation of IBS, and more research 
is, therefore, warranted in order to see alterations in gut 
microbiota in IBS patients with and without extraintestinal 
comorbidities.
Patients included in this study comprised a consistent 
group, with a high prevalence of moderate and severe IBS 
symptoms, and they had a high prevalence of fatigue (84.2%) 
corresponding with our previous study.20 The small size of the 
patient sample and the range of the study populations are weak-
nesses of this study, whereas the control group is smaller than 
the patient group even though mean age values were similar 
in both groups. Future studies with larger patient and control 
groups are, therefore, of interest, in order to further reveal the 
association between cytokine profiles and the comorbidity of 
IBS and fatigue. 
Conclusion
The cytokines IL-5, IL-6, IL-10, and TNF-α may contribute 
to the development of IBS. However, serum levels of cyto-
kines were not significantly different in IBS patients with 
fatigue compared with IBS patients without fatigue. The 
cytokine profiles do not appear to be involved in the patho-
genesis of individual extraintestinal comorbid conditions 
that may accompany IBS. Thus, the significance of cytokine 
levels may be less important than anticipated in search of 
common underlying mechanisms, and other factors including 
alterations in gut microbiota diversity and their metabolites 
should be explored in future studies.
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